What's new

Opinion/decision on a Paediatric investigation plan (PIP): Opdivo, nivolumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0138/2024

Opinion/decision on a Paediatric investigation plan (PIP): Opdivo, nivolumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0138/2024

Jun 12, 2025 - 16:25
 0
Opinion/decision on a Paediatric investigation plan (PIP): Opdivo, nivolumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0138/2024
Opinion/decision on a Paediatric investigation plan (PIP): Opdivo, nivolumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0138/2024
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Amvuttra, vutrisiran, ...

Next Article

Human medicines European public assessment report (EPAR): Sugammadex Piramal, su...

Related Posts

Human medicines European public assessment report (EPAR): Bomyntra, denosumab, Status: Opinion

Human medicines European public assessment report (EPAR...

May 23, 2025  0

Human medicines European public assessment report (EPAR): Menveo, meningococcal group A, C, W-135 and Y conjugate vaccine, Date of authorisation: 15/03/2010, Date of refusal: 17/12/2009, Revision: 37, Status: Authorised

Human medicines European public assessment report (EPAR...

May 23, 2025  0

Start of procedure: Type II variation - extension of in...

May 27, 2025  0